Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Marinobufagenin in urine: a potential marker of predisposition to ethanol and a target for spironolactone. / Kashkin, V.A.; Shekunova, E.V.; Egorov, A.Y.; Bagrov, A.
в: Current Hypertension Reviews, Том 14, № 1, 2018, стр. 35-38 .Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Marinobufagenin in urine: a potential marker of predisposition to ethanol and a target for spironolactone
AU - Kashkin, V.A.
AU - Shekunova, E.V.
AU - Egorov, A.Y.
AU - Bagrov, A.
PY - 2018
Y1 - 2018
N2 - Background and Objective: Previously it was demonstrated that digitalis-like cardiotonic steroid, marinobufagenin (MBG), is implicated in the development of ethanol addiction in rats. We hypothesized that (i) levels of sodium pump ligand, MBG, would be negatively correlated with the amount of ethanol consumed by rats, and (ii) that spironolactone would oppose the MBG induced ethanol-seeking behavior and blood pressure in rats. Methods: Voluntary consumption of 9% alcohol (vs. water) during 10 days period by 11 adult male Wistar rats was studied. Eight weeks after the beginning of the experiment, the animals were divided into two treatment subgroups: high alcohol drinkers (HAD, n=6, daily consumption of ethanol > 4 g/kg) and low alcohol drinkers (LAD, n=5, daily consumption of ethanol < 4 g/kg) rats. Spironolactone treatment (7 days) was started following 3-day habituation to intragastric vehicle administration. Consumption of ethanol and blood pressure were recorded daily. Results: Urinary MBG excretion at baseline was 11.2±0.6 pmoles in HAD rats and 19.1±2.9 pmoles (p<0.05) in LAD rats, respectively. Seven days of spironolactone treatment was associated with reduction in ethanol intake (2.9 g/kg/24 hr), reduction in systolic blood pressure (5 mm Hg), and increase in sodium excretion (1 mmol/24 hr). Conclusion: Levels of MBG may be a predisposing factor to voluntary ethanol intake. Spironolactone, along with antihypertensive effect, decreases ethanol intake.
AB - Background and Objective: Previously it was demonstrated that digitalis-like cardiotonic steroid, marinobufagenin (MBG), is implicated in the development of ethanol addiction in rats. We hypothesized that (i) levels of sodium pump ligand, MBG, would be negatively correlated with the amount of ethanol consumed by rats, and (ii) that spironolactone would oppose the MBG induced ethanol-seeking behavior and blood pressure in rats. Methods: Voluntary consumption of 9% alcohol (vs. water) during 10 days period by 11 adult male Wistar rats was studied. Eight weeks after the beginning of the experiment, the animals were divided into two treatment subgroups: high alcohol drinkers (HAD, n=6, daily consumption of ethanol > 4 g/kg) and low alcohol drinkers (LAD, n=5, daily consumption of ethanol < 4 g/kg) rats. Spironolactone treatment (7 days) was started following 3-day habituation to intragastric vehicle administration. Consumption of ethanol and blood pressure were recorded daily. Results: Urinary MBG excretion at baseline was 11.2±0.6 pmoles in HAD rats and 19.1±2.9 pmoles (p<0.05) in LAD rats, respectively. Seven days of spironolactone treatment was associated with reduction in ethanol intake (2.9 g/kg/24 hr), reduction in systolic blood pressure (5 mm Hg), and increase in sodium excretion (1 mmol/24 hr). Conclusion: Levels of MBG may be a predisposing factor to voluntary ethanol intake. Spironolactone, along with antihypertensive effect, decreases ethanol intake.
KW - Blood pressure
KW - Ethanol
KW - Marinobufagenin
KW - Na/K-ATPase
KW - Predisposition
KW - Rat
KW - Spironolactone
KW - blood pressure
KW - rat
KW - predisposition
KW - ethanol
KW - spironolactone
KW - NA/K-ATPASE
KW - INHIBITION
KW - ENDOGENOUS BUFADIENOLIDE
UR - http://www.scopus.com/inward/record.url?scp=85048980554&partnerID=8YFLogxK
UR - http://www.eurekaselect.com/159723/article
UR - http://www.mendeley.com/research/marinobufagenin-urine-potential-marker-predisposition-ethanol-target-spironolactone
U2 - 10.2174/1573402114666180212115518
DO - 10.2174/1573402114666180212115518
M3 - Article
VL - 14
SP - 35
EP - 38
JO - Current Medical Imaging
JF - Current Medical Imaging
SN - 1573-4056
IS - 1
ER -
ID: 33210575